Vesnarinone and glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice by Honma, Y et al.
Currently, lung cancer is a leading cause of cancer-related adult
deaths, and its incidence continues to rise. The overall response
rate of non-small cell lung cancer (NSCLC) is in the range of
20–30% with 3–5% of complete responses (Donnadieu et al,
1991). The current results of treatment for NSCLC clearly call for
improvements.
Vesnarinone (3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl-1-piper-
azinyl]-2(1H)-quinolinone) is an oral inotropic agent which has
been used for the treatment of chronic heart failure in Japan (OPC-
8212 Multicenter Research Group, 1990). In addition to this
inotropic activity, we and others have shown that vesnarinone has
differentiation-inducing activity in several human haematopoietic
and non-haematopoietic malignant cells (Sato et al, 1995, 1996).
Although the mechanism of differentiation induced by vesnari-
none remains unknown, vesnarinone, alone or in combination with
other differentiation inducers, can significantly induce or enhance
the differentiation of myelomonocytic leukaemia cells (Sato et al,
1996). Vesnarinone is effective when administered perorally, and
the serum level of vesnarinone can be obtained up to 30 mg ml–1
(Miyamoto and Sasabe, 1984; Taira et al, 1984). Treatment with
30 mg ml–1 of vesnarinone markedly enhanced the morphological
differentiation of HL-60 and U937 cells induced by suboptimal
concentrations of some differentiation inducers, including retinoic
acid (Sato et al, 1996). The pharmacokinetics and toxicity of
vesnarinone have already been studied (Miyamoto and Sasabe,
1984; Taira et al, 1984) and it has been approved for use as a
cardiotonic drug. These results suggest that combined treatment
with vesnarinone and other non-toxic drugs may be a new potent
therapy for some types of malignancies.
Cell cycle checkpoints represent a new set of potential targets
for chemotherapeutic compounds (Hartwell and Kastan, 1994;
Karp and Broder, 1995). Physiological and/or non-genotoxic
compounds that induce cell cycle arrest and/or apoptosis in cancer
cells should be useful for cancer chemotherapy, since DNA-
damaging agents produce serious side-effects in the host and
sometimes induce secondary leukaemia and tumours. Therefore, it
is worthwhile to search for less toxic drugs that have been used in
clinical trials for other diseases, to develop a new therapy for
malignancies.
In the present study, we examined the growth-inhibitory effect
of vesnarinone on human non-small lung carcinoma cell lines in
combination with various compounds, and found that vesnarinone
and glucocorticoids had synergistic on the growth of lung carci-
noma cells in vitro and in vivo.
MATERIALS AND METHODS
Chemicals
Vesnarinone was obtained from Otsuka Pharmaceutical Company
(Tokushima, Japan), dissolved in dimethyl sulphoxide
(DMSO) and diluted with phosphate-buffered saline (PBS).
Dexamethasone (Dex), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), p-nitrophenyl phosphate, RNase A
and propidium iodide were obtained from Sigma Chemical Co.
(St Louis, MO, USA). DMSO and all other chemicals were
obtained from Wako Pure Chemicals (Osaka, Japan).
Cells and cell culture
Human lung carcinoma EBC-1, LK2, PC9, ABC-1 and A549 cell
lines were maintained in RPMI-1640 medium (GIBCO, Great
Island, NY, USA) supplemented with 10% heat-inactivated fetal
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bovine serum and non-essential amino acids of modified Eagle’s
medium (MEM) at 37°C in a humidified atmosphere of 5% CO2 in
air (Goto et al, 1994, 1996). The cell lines were kindly supplied
from the Japanese Cancer Research Resources Bank (Tokyo,
Japan).
Assay of cell growth
The cells were seeded at a concentration of 2 ´ 104 ml–1 in a multi-
dish (Nunc, Roskilde, Denmark). After culture with or without the
test compounds for 7 days, viable cells were examined by MTT
assay (Goto et al, 1994). Briefly, 100 ml of MTT solution
(5 mg ml–1 in PBS) were added to each well. After incubation with
MTT for 4 h, the cells were centrifuged at 1000 g for 10 min. The
precipitates were dissolved in 1 ml of DMSO and their absorptions
at 560 nm were determined.
Assay of the cumulative cell number
The cell density of untreated cells was kept at 1–10 ´ 105 ml–1 to
maintain continuous logarithmic growth. The cells were collected
by treatment with 0.1% trypsin–0.04% EDTA (GIBCO, Grand
Island, NY, USA) for 5 min with gentle shaking, and were trans-
ferred every 3 days. The cell density of the treated cells was kept at
3–8 ´ 105 ml–1 to maintain cells in growing phase, and transferred
every 3 or 6 days by the trypsinization. The treatment with trypsin
did not affect the cell morphology and adhesiveness. The cell
number was counted with a Coulter Counter (Model ZBI; Coulter
Electronics, Hialeah, FL, USA). The cumulative cell number was
calculated from the counts and dilution used when feeding the
culture.
Assay of alkaline phosphatase activity
Alkaline phosphatase activity is a marker for the maturation of
type II pneumocytes and is not expressed in other alveolar cells
(Edelson et al, 1988; McCormick et al, 1995). Cells were washed
twice with cold PBS, resuspended to a cell density of 107 cells ml–1
of cold distilled water, and sonicated for 10 s. The reaction
mixture contained 50 mM glycine–NaOH (pH 10.5), 0.5 mM
magnesium chloride, 4.2 mM p-nitrophenyl phosphate, and the cell
lysate in a total volume of 0.4 ml. The incubation was allowed to
proceed for 60 min at 37°C, and the reaction was then stopped by
adding of 1 ml of 0.1 M NaOH. The absorbance of p-nitrophenol
was determined at 410 nm to calculate enzyme activity.
Cell cycle analysis
The cell cycle was analysed using propidium iodide-stained
nuclei. Samples of 2 ´ 106 cells were harvested at the time points
indicated, washed in ice-cold PBS, fixed by the addition of 100%
ethanol and left for 30 min on ice. The cell pellet was washed and
suspended in 200 ml of 1.12% sodium citrate containing RNase A
(250 mg ml–1) for 30 min at room temperature. Thereafter, the cells
were stained with 50 mg ml–1 of propidium iodide in the presence
of 1.12% sodium citrate and analysed in a fluorescence-activated
cell sorter.
Western blot analysis of Rb protein
Cells were washed once with cold PBS, lysed by sonication for
30 s at a concentration of 2 ´ 107 cells ml–1 in sample buffer, and
then resolved on 7.5% sodium dodecyl sulphate polyacrylamide
gels (SDS-PAGE) as described by Laemmli (1970). The proteins
were transferred electrophoretically from the gel to an Immobilon-
P membrane (Millipore) and immunoblotted with anti-Rb protein
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The
proteins were quantified by an enzyme-linked immunosorbent
assay as described previously (Kanatani et al, 1993).
Transplantation of lung carcinoma cells into nude mice
Female athymic nude mice with a BALB/c genetic background
were supplied by CLEA Japan (Tokyo, Japan). The in vivo exper-
iments were performed in accordance with the guidelines of our
institute (Guide for Animal Experimentation, Saitama Cancer
Center). Mice were inoculated subcutaneously (s.c.) with 106
EBC-1 or PC9 cells. Mice were given a daily intraperitoneal (i.p.)
injection of 0.2 ml of PBS including prednisolone (300 mg kg–1)
and/or peroral administration of vesnarinone (5 mg kg–1), with the
first injection given 4 days after the inoculation of tumour cells.
Tumour size was measured with vernier calipers every day.
Statistical analysis was performed using Student’s t-test.
RESULTS
Combined effects of vesnarinone and Dex on the
growth of lung carcinoma cell lines
To measure the growth-inhibitory effects of drugs on lung carci-
noma cells, the number of viable cells was determined by the MTT
assay after 7 days of exposure to various concentrations of drugs.
The growth-inhibitory effects of drugs were examined by deter-
mining the concentrations of drugs required to reduce the cell
number to one-half that of untreated cells (IC50). Vesnarinone
inhibited the growth of lung carcinoma cells in a dose-dependent
manner, and the IC50 of vesnarinone in squamous cell carcinoma
LK2 cells was lower than 10 mg ml–1. However, the growth of the
other NSCLC cells was less sensitive, and the respective IC50s
were more than 20 mg ml–1 (IC50: 23.4, 21.3, 29.7 and 30.6 mg ml–1
in EBC-1, PC9, ABC-1 and A549 cells respectively). Vesnarinone
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Figure 1 Effects of Dex and vesnarinone on the growth of EBC-1 cells.
Cells were cultured with various concentrations of Dex in the presence
of 0 (l l), 10 (l), or 20 (n) mg ml–1 of vesnarinone for 7 days. Values are
means ± s.d. of four determinations98 Y Honma et al
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is effective when administered perorally, and the serum level of
vesnarinone can be obtained up to 30 mg ml–1 (Miyamoto and
Sasabe, 1984; Taira et al, 1984). These results suggest that treat-
ment with vesnarinone alone is clinically effective in only a
limited number of cases of NSCLC.
Next, we examined the growth-inhibitory effect of various
compounds in combination with vesnarinone. Of the compounds
tested, Dex more than additively enhanced the vesnarinone-
induced inhibition of the growth of lung carcinoma EBC-1 cells
(Figure 1). To determine the structure required for the growth inhi-
bition, the effect of various steroids was examined. The growth
inhibition in the presence of vesnarinone was closely correlated
with glucocorticoid activity (Table 1). The growth-inhibitory effect
of vesnarinone was not enhanced by retinoic acid (10–9–10–6 M),
1 a, 25-dihydroxyvitamin D3 (10–9–10–5 M), sodium butyrate
(0.1–2.5 mM), interferon-a (1–3000 IU ml–1), actinomycin D
Table 1 Effects of various steroids on the growth of EBC-1 cells in the
presence of vesnarinone
Steroid (10–8 M) Cell number (% of control)
–Vesnarinone +Vesnarinone
None 100 86.2 ± 3.7
Dexamethasone 92.8 ± 4.9 38.9 ± 2.1
Prednisolone 95.4 ± 5.2 39.5 ± 3.2
Hydrocortisone 98.8 ± 5.5 44.6 ± 3.4
Corticosterone 99.3 ± 5.2 56.8 ± 3.6
11-Epicortisol 99.2 ± 5.6 82.3 ± 4.2
Progesterone 93.9 ± 4.9 83.9 ± 3.9
11b-Estradiol 98.4 ± 5.1 84.7 ± 4.3
Testosterone 99.1 ± 4.7 86.0 ± 3.5
Cells were treated with various steroids in the presence or absence of
10 mg ml–1 vesnarinone for 7 days, and the number of viable cells was
determined by MTT assay. Data represent means from three experiments
± s.d.
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Figure 2 Effects of Dex and vesnarinone on the growth of human lung
cancer cells. Cells were cultured with 10–9 M Dex (n n), 10 mg ml–1 vesnarinone
(n), and 10–9 M Dex plus 10 mg ml–1 vesnarinone (n n) for 7 days. n, untreated
cells. Values are means of three determinations
Table 2 Combined effects of Dex and vesnarinone on the growth of EBC-1
cells
Regimen Days 1–4 Days 5–8 Growth inhibition
(%)
1–1 None None 0 ± 0.1
1–2 Dex 4.2 ± 0.2
1–3 Ves 33.3 ± 1.9
1–4 Dex+Ves 44.2 ± 2.3
2–1 Dex None 3.1 ± 0.2
2–2 Dex 2.9 ± 0.2
2–3 Ves 36.2 ± 2.5
3–1 Ves None 13.2 ± 1.4
3–2 Dex 27.8 ± 1.8
3–3 Ves 46.8 ± 3.3
4–1 Dex+Ves None 52.6 ± 3.5
4–2 Dex+Ves 85.3 ± 4.1
Cells were cultured for 4 days in the presence or absence of 10 nM Dex,
10 mg ml–1 vesnarinone (Ves), or 10 nM Dex plus 10 mg ml–1 Ves. On day 4,
the cultures were washed with fresh medium, and the cultures reincubated
in the presence or absence of the same concentration of Dex or Ves.
Means ± s.d. of three determinations.
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Figure 3 Proliferation of EBC-1 cells in long-term culture with Dex and
vesnarinone. Cells were cultured without (n) or with 2 ´ 10–8 M Dex (l),
10 mg ml–1 vesnarinone (s), or 2 ´ 10–8 M Dex plus 10 mg ml–1 of vesnarinone
(u). Open symbols, cells were washed and then cultured without drugs. Cells
were treated with Dex plus vesnarinone for 6 (l l), 12 (n n) and 18 (s s) days,
and then washed and reincubated without drugs for further 6 days. Data are
means of three separate experimentsAnti-tumour effect of vesnarinone 99
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(0.2–16 nM), cytosine arabinoside (10–10–10–8 M), or doxorubicin
(1–50 nM) (data not shown). The synergistic effect of vesnarinone
and Dex was observed in the growth of all of the NSCLC cells
tested (Figure 2).
The effect of the time of the addition of Dex or vesnarinone on
growth inhibition was examined. Pretreatment with Dex did not
affect the growth-inhibitory activity of vesnarinone plus Dex, and
the delayed addition of Dex also did not affect growth inhibition
(data not shown). Table 2 indicates that simultaneous treatment is
the most effective to evoke the synergistic effect of vesnarinone
and Dex.
The effect of continuous treatment with 10 mg ml–1 of vesnari-
none and 2 ´ 10–8 M Dex added simultaneously on the prolifera-
tion of EBC-1 cells was examined for 24 days. The cell density
was kept at 1–10 ´ 105 ml–1 to maintain cells in the growing phase,
and the cumulative cell number was calculated from the counts
and dilution used when feeding the culture. Continuous treatment
with 10 mg ml–1 of vesnarinone or 2 ´ 10–8 M Dex only slightly
inhibited the growth of EBC-1 cells. However, combined treat-
ment with vesnarinone and Dex caused significant growth inhibi-
tion (Figure 3). When the cells were treated for 18 days, and then
washed and cultured without the drugs, cell growth was greatly
inhibited at day 24, indicating that the growth-inhibitory effect of
vesnarinone and Dex was irreversible in long-term culture. These
results suggest that the combined treatment has therapeutic value
in the chemotherapy of some lung cancers.
Effects of Dex and vesnarinone on morphological
changes and alkaline phosphatase activity of EBC-1
cells
Dex induced morphological changes in EBC-1 cells, although the
growth of EBC-1 cells was not essentially affected by even a high
concentration of Dex. Untreated EBC-1 cells were spindle-shaped,
while Dex-treated cells adhered closely to each other and were
cuboidal and polygonal (Figure 4). Vesnarinone alone did not
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Figure 4 Morphological changes in human lung carcinoma EBC-1 cells by
Dex plus vesnarinone. Cells were treated without (A) or with (B) 2 ´ 10–8 M
Dex for 2 days. Original magnification ´ 400
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Figure 5 Induction of alkaline phosphatase activity in lung carcinoma cells
by Dex in combination with vesnarinone. (A) EBC-1 cells were treated with
Dex in the presence of 0 (n), 10 (l), or 20 (s) mg ml–1 of vesnarinone for
7 days. (B) ABC-1 and PC9 cells were treated with 10–8 M Dex and/or
10 mg ml–1 of vesnarinone for 7 days. Values are means ± s.d. of four
determinations100 Y Honma et al
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induce significant changes in the morphology of EBC-1 cells, but
Dex-induced morphological changes were slightly enhanced by
vesnarinone.
Since alkaline phosphatase activity is a marker for the matura-
tion of type II pneumocytes (Edelson et al, 1988; McCormick et al,
1995), we measured the effect of Dex and vesnarinone on alkaline
phosphatase activity in EBC-1, ABC-1 and PC9 cells. Dex signifi-
cantly induced alkaline phosphatase activity in the cells, as in a
previous report that Dex induces alkaline phosphatase activity in
A549 cells (McCormick et al, 1995). Vesnarinone alone did not
induce enzyme activity in the cells, but did significantly enhance
the Dex-induced alkaline phosphatase activity in EBC-1 (Figure
5A), ABC-1 and PC9 cells (Figure 5B).
Cell cycle analysis of EBC-1 cells treated with
vesnarinone and Dex
To understand the nature of the joint action of vesnarinone and
Dex on the proliferation of EBC-1 cells, we exposed the cells to
10 mg ml–1 of vesnarinone and 2 ´ 10–8 M Dex, and then measured
the cell cycle distribution after 4 days (Figure 6). This treatment
induced growth arrest of the cells at the G0–G1 phase. There were
no appreciable apoptotic cells in a culture incubated with
vesnarinone and Dex at 7 days. The G1 arrest in cells treated with
vesnarinone plus Dex was more prominent than that in cells
cultured in serum-free medium or under confluent conditions
(Table 3).
Dephosphorylation of Rb protein in EBC-1 cells treated
with vesnarinone and Dex
A reasonable hypothesis is that arrest of the cell cycle in G1 was
caused by dephosphorylation of Rb protein, whereas the transient
G2 block was independent of Rb protein dephosphorylation
(Weinberg, 1995). Phosphorylation of Rb protein of EBC-1 cells
treated with vesnarinone and Dex was analysed by Western
blotting using anti-Rb protein monoclonal antibody (Figure 7). In
untreated cells, Rb protein was hyperphosphorylated and migrated
slower, while Rb protein was under-phosphorylated and migrated
faster in cells treated with vesnarinone and Dex. Phosphorylation
began to decrease after 24 h of treatment.
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Figure 6 Induction of G1 arrest in EBC-1 cells treated with Dex plus vesnarinone. Cells were cultured without (A) or with (B) 2 ´ 10–8 M Dex plus 10 mg ml–1 of
vesnarinone for 4 days, and DNA histograms were then analysed
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Figure 7 Western blot for Rb protein from EBC-1 cells treated with Dex and
vesnarinone. Cells were treated without (1) or with 2 ´ 10–8 M Dex (2),
10 mg ml–1 of vesnarinone (3), or 2 ´ 10–8 M Dex plus 10 mg ml–1 of
vesnarinone (4) for 2 days. ppRb; phosphorylated Rb protein, pRb;
dephosphorylated Rb protein
Table 3 Effects of Dex and vesnarinone on the cell-cycle distribution of
EBC-1 cells
Treatment Cell cycle distribution (% ± s.d.)
G1 SG 2+M
Rapidly growing 47.5 ± 4.8 38.2 ± 3.5 14.3 ± 2.1
Confluent 62.4 ± 6.5 23.5 ± 2.8 14.1 ± 1.7
Serum-free 63.2 ± 5.9 21.8 ± 2.3 15.0 ± 1.4
Dex 54.5 ± 5.9 26.9 ± 2.4 18.6 ± 2.2
Ves 86.6 ± 8.2 2.3 ± 0.4 11.1 ± 1.2
Dex+Ves 97.1 ± 9.4 0 2.9 ± 0.3
EBC-1 cells were incubated with or without 20 mg ml–1 of vesnarinone (Ves)
in the presence or absence of 2 ´ 10–8 M Dex for 7 days. Cells were cultured
at a cell density below 3 ´ 105 ml–1 in 10% serum-containing medium (rapidly
growing cells) or in serum-free medium (serum-free) for 4 days. Means ± s.d.
of three determinations.Anti-tumour effect of vesnarinone 101
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Effect of vesnarinone and prednisolone on the in vivo
growth of EBC-1 cells as xenografts
The in vitro studies described above suggested that combined
treatment with vesnarinone and glucocorticoid should be more
effective therapeutically than treatment with vesnarinone or gluco-
corticoid alone. Although Dex was the most potent steroid tested
in the in vitro studies, preliminary results indicated that pred-
nisolone was more effective than Dex in the in vivo experiments.
Therefore, we used prednisolone for the further in vivo experi-
ments. The combined treatment significantly inhibited the growth
of EBC-1 cells as xenografts (Figure 8). At day 20 after the inocu-
lation of tumour cells, the mean tumour volumes of untreated,
prednisolone-, vesnarinone- and prednisolone plus vesnarinone-
treated nude mice were 1.82 ± 0.12, 1.32 ± 0.16, 0.98 ± 0.13, and
0.36 ± 0.11 cm3 (± s.d.) respectively. These results indicate that the
combination of vesnarinone and prednisolone is more effective
therapeutically than vesnarinone or prednisolone alone, and the
anti-tumour effect of the combined treatment was statistically
significant (P < 0.01). The combined treatment was also effective
in xenografts of lung carcinoma PC9 cells (Figure 8).
DISCUSSION
Glucocorticoid receptor is widely distributed in human tissues,
but receptor activation and regulation are tissue-specific.
Glucocorticoids accelerate the appearance of pulmonary surfactant
in developing mammalian fetal lungs (Liggins, 1969; DeLemos
et al, 1970; Liggins and Howie, 1972), and hydrocortisone inhibits
the rate of mitosis in fetal rabbit lung (Jones et al, 1978).
Glucocorticoids have slight growth-inhibitory effects on some
NSCLC cells (Kikkawa et al, 1971; Mattern et al, 1985; McLean
et al, 1986), suggesting that lung cancer may be influenced by
glucocorticoid therapy.
Growth of human lung alveolar carcinoma A549 cells is dose-
dependently inhibited by glucocorticoids, and this growth inhibi-
tion is associated with an induction of differentiated function,
although the differentiation of lung cancer cells has not been
well characterized (Kikkawa et al, 1971; Mattern et al, 1985;
McCormick et al, 1995). Dex induced morphological changes as
well as alkaline phosphatase activity in EBC-1 cells, and the same
concentrations were effective in combination with vesnarinone,
suggesting that these phenotypic changes were partly associated
with the sensitization of EBC-1 cells to vesnarinone. Other gluco-
corticoids were also effective in inhibiting growth in combination
with vesnarinone (Table 1). The growth-inhibitory effect of Dex
plus vesnarinone was observed in all of the NSCLC cells tested. A
significant incidence of specific, high-affinity receptors for gluco-
corticoids is present in NSCLC (Chaudhuri et al, 1982; Beattie
et al, 1985; Hofmann et al, 1995). The growth of approximately
one-third of the NSCLC cell lines was inhibited by Dex, although
the growth-inhibitory effect was modest in most of the cell lines
(Hofmann et al, 1995). Glucocorticoids can be administered to
patients with NSCLC with tolerable side-effects, although the
steroids alone have no anticancer effect in lung cancer patients.
Glucocorticoids more than additively enhanced vesnarinone-
induced growth inhibition. Therefore, treatment with glucocorti-
coids in combination with vesnarinone may be a strategy for
treating lung cancer with low sensitivity to conventional
chemotherapy.
Cyclin-dependent kinase-mediated phosphorylation of Rb pro-
tein is prevented by cyclin-dependent kinase inhibitors such as
p21 (WAF1/CIP1/SDI1) (Weinberg, 1995). Therefore, we exam-
ined the expression of p21 mRNA in EBC-1 cells that had been
treated with vesnarinone and Dex. Untreated EBC-1 cells
expressed a detectable level of p21 mRNA, but this expression
was not affected by vesnarinone and/or Dex (data not shown).
Similar results were obtained when the expression of p21 protein
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Figure 8 Effects of prednisolone and vesnarinone on the growth of EBC-1 (A) and PC9 (B) cells as xenografts. Mice received daily p.o. administration of
vesnarinone (s, u) and i.p. injection of prednisolone (l, u). n, untreated mice. Values are means (± s.d.) of 7–10 mice102 Y Honma et al
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was analysed by immunoblot. In most NSCLC, p21 protein and
RNA were expressed at higher levels than in the corresponding
normal tissues, and p21 was expressed independent of changes in
p53 gene/protein (Marchetti et al, 1996). These results suggest that
the dephosphorylation of Rb protein by vesnarinone and Dex is
independent of the induction of p21 cyclin-dependent kinase
inhibitor.
Induction of protein phosphatase activity rather than p21 is
responsible for chemotherapy-induced Rb dephosphorylation and
consequent G1 arrest in human leukaemia cells (Christoffersen et
al, 1994; Dou et al, 1995). Rb protein phosphatase may be predom-
inantly responsible for p53-independent Rb dephosphorylation, G1
arrest and apoptosis (Alberts et al, 1993; Ludlow et al, 1993;
Christoffersen et al, 1994; Dou et al, 1995). Preliminary experi-
ments indicate that combined treatment with vesnarinone and Dex
induces Rb protein phosphatase activity in EBC-1 cells (data not
shown), although we cannot rule out the participation of Rb
protein kinase inhibitors other than p21.
Solid tumour cells are generally more resistant to anticancer
drugs and apoptosis-inducing agents than leukaemia cells.
However, the growth-inhibitory effects of vesnarinone were more
prominent in solid tumour cells than in leukaemia cells (Sato et al,
1995, 1996). The actions of many anticancer drugs are mediated
by the induction of p53 and/or p21, but the growth-inhibitory
effects of vesnarinone on EBC-1 cells were independent of p21.
Since many lung cancer cells have an impaired p53/p21-signalling
system, a p53/p21-independent mechanism would be important for
regulating the abnormal growth of lung cancer cells.
Transforming growth factor (TGF)-b inhibits the growth and
induces differentiation of several lung and other carcinoma cells
(Twardzik et al, 1989; Chakrabarty et al, 1990; Schroy et al, 1990).
Glucocorticoids synergistically inhibit the growth of monocytoid
leukaemia cells in combination with a low concentration of TGF-b
(Kanatani et al, 1996). Vesnarinone, like TGF-b, induces the
differentiation of human erythroleukaemia HEL cells (Sato
et al, 1996). However, TGF-b production was not induced by
vesnarinone and/or Dex in EBC-1 cells, and TGF-b did not have a
synergistic effect with Dex in the growth inhibition of EBC-1 cells
(data not shown). These results suggest that TGF-b is not involved
in the growth inhibition of EBC-1 cells by Dex and vesnarinone.
Vesnarinone and glucocorticoids are non-genotoxic, and clini-
cally available. Vesnarinone has been approved for use as a
cardiotonic drug. The serum level of vesnarinone can be obtained
up to 30 mg ml–1 (Miyamoto and Sasabe, 1984; Taira et al, 1984).
There is no appreciable toxicity of vesnarinone on oral administra-
tion, since absorption of the drug is saturated due to the low solu-
bility. On rare occasion granulocytopenia (less than 2%) was
observed by vesnarinone in humans, but it is reversible when the
administration is stopped. Therapy with glucocorticoids or vesnar-
inone alone may be effective in only a very limited number of
cases of NSCLC, since glucocorticoids only have a marked anti-
proliferative effect on A549 cells (Jones et al, 1978). Vesnarinone
alone has significant anti-tumour activity against human salivary
cancer cells in athymic nude mice (Sato et al, 1995). In human
NSCLC cell lines, vesnarinone only had such a significant effect
on LK2 cells. However, the combination of vesnarinone and Dex
had a significant anti-proliferative effect on all of the lung cancer
cell lines tested, and the anti-proliferative effect in vivo was
observed without any significant adverse effects. This may be a
promising approach to lung cancer therapy which avoids many of
the disadvantages of cytotoxic agents.
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